Herpes simplex glycoprotein vaccine - GSK
Alternative Names: Genital herpes prophylaxis vaccine - GSK; GSK208141; HSV gD-t2; SimplirixLatest Information Update: 05 Nov 2023
At a glance
- Originator Genentech
- Developer GlaxoSmithKline; National Institute of Allergy and Infectious Diseases
- Class Protein vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Herpes simplex virus infections
Most Recent Events
- 30 Sep 2010 Discontinued - Phase-III for Herpes simplex virus infections in Canada (IM)
- 30 Sep 2010 Discontinued - Phase-III for Herpes simplex virus infections in European Union (IM)
- 30 Sep 2010 Discontinued - Phase-III for Herpes simplex virus infections in USA (IM)